Epizyme, Inc
EPZM
EPZM was delisted on the 11th of August, 2022.
121 hedge funds and large institutions have $965M invested in Epizyme, Inc in 2019 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 41 increasing their positions, 28 reducing their positions, and 20 closing their positions.
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
137% more capital invested
Capital invested by funds: $407M → $965M (+$557M)
80% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 20
46% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 28
15% more funds holding
Funds holding: 105 → 121 (+16)
80% less call options, than puts
Call options by funds: $266K | Put options by funds: $1.31M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$38.9M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$24.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$20.2M |
| 4 |
AG
Artal Group
Luxembourg
|
+$19.6M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$18.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$13M |
| 2 |
VOYA Investment Management
Atlanta,
Georgia
|
-$8.08M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$4.62M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$4.36M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$3.47M |
EPZM Hedge Fund Activity: Q1 2019 in Review
121 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q1 2019, worth a combined $965M — up 137% from $407M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new EPZM positions and 20 closed out — a net gain of 16 holders — while 41 added to existing stakes and 28 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $38.9M. The largest seller was Jennison Associates, cutting an estimated $13M.
- 121 institutional investors held Epizyme, Inc (EPZM) as of Q1 2019, up from 105 in Q4 2018.
- Funds reported $965M of Epizyme, Inc stock for Q1 2019, up 137% quarter-over-quarter.
- 36 funds opened new Epizyme, Inc positions in Q1 2019 and 20 closed out, a net change of +16 holders.
- The largest Epizyme, Inc buyer in Q1 2019 was Consonance Capital Management, an estimated $38.9M added.
- The largest Epizyme, Inc seller in Q1 2019 was Jennison Associates, an estimated $13M sold.
Based on aggregated 13F filings for Q1 2019.